Piper Sandler lowered the firm’s price target on Keros Therapeutics (KROS) to $15 from $40 and keeps an Overweight rating on the shares. The company announced its decision to stop dosing within the 1.5 mg/kg and placebo arms of cibotercept’s ongoing Phase II TROPOS trial in pulmonary arterial hypertension following additional pericardial effusion events, along with an overall risk-benefit analysis, the analyst tells investors in a research note. The firm says this follows the decision last month to stop dosing in the 3.0 and 4.5 mg/kg arms for that same reason. Moving forward, KER-065 now becomes the company’s primary wholly-owned clinical stage asset, says Piper.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target lowered to $41 from $44 at Scotiabank
- Keros Therapeutics price target lowered to $23 from $63 at Oppenheimer
- Keros Therapeutics price target lowered to $32 from $33 at BofA
- Big banks report Q4 beats, QXO proposes to buy Beacon: Morning Buzz
- Morning Movers: Wells Fargo and Citi gain following Q4 earnings